Please provide your email address to receive an email when new articles are posted on . A phase 2 study included 129 individuals with MS randomized to receive frexalimab or placebo for 24 weeks.

Many recovering drug addicts (myself included) have a recurring nightmare: You wake up one morning and suddenly all of the work you have put into staying sober is gone. Maybe you’re returning to ...

Macklemore revealed he has been sober for nearly two years after relapsing during the COVID-19 pandemic. “I relapsed during the first summer of Covid,” the “Thrift Shop” rapper, 39, wrote in a TikTok ...

The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...

On December 28, 2022, the U.S. Food and Drug Administration (FDA) approved Briumvi (ublituximab), a disease-modifying therapy (DMT) to treat relapsing forms of multiple sclerosis (RMS) in adults, ...

Please provide your email address to receive an email when new articles are posted on . Many clinicians overlook neurohormonal and metabolic adaptations that make weight loss difficult. Obesity ...

We know so much more about multiple sclerosis (MS) than we used to. But one important theme is that we’ve become much better at treating the relapsing form of this disease and changing its natural ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

We report on a case of fever of unknown origin in which 18 F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) was instrumental in depicting cartilage inflammation, which eventually led to a ...

Zenas BioPharma’s stock climbed 33% following a positive mid-phase trial readout for its lead candidate, obexelimab, in relapsing multiple sclerosis (RMS). During the Phase II MoonStone study ...